MedTrace Logo

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

NCT04811469 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of CBP-174 after a single oral dose in healthy adult subjects.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

CBP-174

CBP-174 oral solution, given once

DRUG

Placebo

Placebo oral solution, given once

Sponsors & Collaborators

  • Connect Biopharma Australia Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Australia Connect · Connect Biopharma Australia Pty Ltd

  • Suzhou Connect · Connect Biopharm LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2022-05-14
Completion
2022-05-21

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811469 on ClinicalTrials.gov